CD4 and non-small cell lung carcinoma: The percentages of lymphocyte subsets (CD4+, CD8+ T cells, B and NK cells) could serve as predictive biomarkers of immunotherapy efficacy and progression-free survival (PFS) in NSCLC, but it did not analyze the AC of lymphocyte subsets (29).